TEM vs. GH: Which AI in Precision Oncology Stock Has More Upside Now?

Key Takeaways GH raised 2025 revenue guidance to $880-$890M, driven by rising test volume and ASPs. TEM posted 75% revenue growth and a $200M foundation model deal but remains unprofitable. GH expects breakeven for non-screening ops by Q4 2025, with lower cash burn excluding Shield.Tempus AI (TEM) and Guardant Health (GH) are two dominant players in the field of AI-powered precision oncology. Tempus, newly public and rapidly scaling, reported a 75% year-over-year revenue growth in the first quarter of 202 ...